Expertise in
12
conditions

Dr. Samuel S. Lentz

Oncology
North Carolina Baptist Hospital
1 Medical Ctr Blvd, 
Winston Salem, NC 
Accepting New Patients
Referral may be required
Before you request
Expertise in
12
conditions
North Carolina Baptist Hospital
1 Medical Ctr Blvd, 
Winston Salem, NC 

Overview

Samuel Lentz is an Oncologist practicing medicine in Winston Salem, North Carolina.

Dr. Lentz is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Lymphadenectomy, and Bladder Reconstruction.

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 20 clinical trials. Dr. Lentz is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in NC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

North Carolina Baptist Hospital
1 Medical Ctr Blvd, Winston Salem, NC 27103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase II Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With HIPEC in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
A Phase II Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With HIPEC in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Enrollment Status: Completed
Publish Date: August 10, 2026
Intervention Type: Other, Drug, Procedure
Study Drugs: HIPEC, Carboplatin
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Paclitaxel, Ruxolitinib phosphate
Study Phase: Phase 1/Phase 2
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Enrollment Status: Unknown
Publish Date: May 03, 2024
Intervention Type: Other
Study Phase: Not Applicable
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Enrollment Status: Unknown
Publish Date: May 03, 2024
Intervention Type: Other, Procedure
Study Phase: Not Applicable
View 9 Less Clinical Trials

13 Total Publications

A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.
A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.
Journal: Gynecologic oncology
Published: April 16, 2026
Similar Doctors
Expertise in
32
conditions
Expertise in
32
conditions
Referral may be required

North Carolina Baptist Hospital

1 Medical Ctr Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-713-5440
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bayard Powell is an Oncologist practicing medicine in Winston Salem, North Carolina. Dr. Powell is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Leukemia, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration. Dr. Powell is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Atrium Health Wake Forest Baptist

S Hawthorne Rd, 
Winston Salem, NC 
 (1.5 miles away)
336-713-5440
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Glenn Lesser is an Oncologist practicing medicine in Winston Salem, North Carolina. Dr. Lesser is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Astrocytoma, Glioma, and Bone Marrow Aspiration. Dr. Lesser is currently accepting new patients.

Expertise in
16
conditions
Dr. Matthew J. Wieduwilt
Hematology | Oncology
Expertise in
16
conditions
Dr. Matthew J. Wieduwilt
Hematology | Oncology
Referral may be required

North Carolina Baptist Hospital

1 Medical Ctr Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-713-5440
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Wieduwilt is a Hematologist and an Oncologist practicing medicine in Winston Salem, North Carolina. Dr. Wieduwilt is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Wieduwilt is currently accepting new patients.

Frequently Asked Questions about Dr. Samuel S. Lentz

How do I make an appointment with Dr. Samuel S. Lentz?

You can book an appointment with Dr. Samuel S. Lentz by calling their office at 336-713-6178. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Samuel S. Lentz a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Samuel S. Lentz is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Samuel S. Lentz specialize in?

While Dr. Samuel S. Lentz is a Oncology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Sertoli-Leydig Cell Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Samuel S. Lentz participate in research or clinical trials?

Yes. Dr. Samuel S. Lentz has published 13 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Samuel S. Lentz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Samuel S. Lentz accept my insurance?

Dr. Samuel S. Lentz accepts most major insurance plans, including Aetna and AmeriHealth. We recommend calling the office directly at 336-713-6178 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lentz's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 7 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile